GlassScriptPhysician profile
Shandrea Rodriguez
NPI 1629278379
$7,694.68
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,735 · 2022: $2,913 · 2023: $46.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $681.92 | 2021-2022 | |
| Abbvie INC. | $675.29 | 2021-2023 | |
| Novo Nordisk INC | $673.32 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $528.37 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $520.89 | 2021-2022 | |
| Glaxosmithkline, LLC. | $504.73 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $465.73 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $365.98 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $353.61 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $253.62 | 2021-2022 | |
| Daiichi Sankyo INC. | $210.44 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.39 | 2021-2022 | |
| Mylan Specialty L.P. | $194.92 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $170.96 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $163.83 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $142.62 | 2021 | |
| Lundbeck LLC | $140.49 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $134.33 | 2021-2022 | |
| Lilly USA, LLC | $121.30 | 2021 | |
| Eisai INC. | $106.69 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.54 | 2022 | |
| Merck Sharp & Dohme LLC | $96.88 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $90.30 | 2022 | |
| Amarin Pharma, INC. | $77.74 | 2021-2022 | |
| Astellas Pharma US INC | $69.52 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $59.09 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.31 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.70 | 2022 | |
| Almatica Pharma LLC | $38.31 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $36.36 | 2022 | |
| Antares Pharma, INC. | $33.47 | 2022 | |
| Bausch Health US, LLC | $20.35 | 2021 | |
| Cmp Pharma, INC. | $18.73 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.71 | 2022 | |
| Exact Sciences Corporation | $17.69 | 2023 | Cologuard Collection Kit |
| Sun Pharmaceutical Industries INC. | $15.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shandrea Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.